(MO) Altria - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US02209S1033
Stock: Cigarettes, Cigars, Smokeless-Tobacco, Nicotine-Pouches, E-Vapor
Total Rating 64
Risk 97
Buy Signal -0.93
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 7.00% |
| Yield on Cost 5y | 14.44% |
| Yield CAGR 5y | 4.26% |
| Payout Consistency | 98.2% |
| Payout Ratio | 62.0% |
| Risk 5d forecast | |
|---|---|
| Volatility | 21.4% |
| Relative Tail Risk | -6.90% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.08 |
| Alpha | 25.33 |
| Character TTM | |
|---|---|
| Beta | -0.003 |
| Beta Downside | 0.158 |
| Drawdowns 3y | |
|---|---|
| Max DD | 16.40% |
| CAGR/Max DD | 1.17 |
Description: MO Altria January 28, 2026
Altria Group, Inc. (NYSE: MO) manufactures and distributes a portfolio of combustible and oral tobacco products in the United States, anchored by the Marlboro cigarette brand and complemented by Black & Mild cigars, Copenhagen/Skoal smokeless tobacco, on! nicotine pouches, and NJOY ACE e-vapor devices. Sales are primarily channeled through distributors and large retail chains, and the company traces its corporate lineage back to 1822, with headquarters in Richmond, Virginia.
In its most recent quarter (Q3 2025), Altria reported net revenue of approximately $3.2 billion, a 5 % year-over-year increase driven largely by a 3 % price hike on premium cigarette lines and growth in the on! nicotine-pouch segment, which posted a 12 % sales acceleration. Adjusted earnings per share rose to $3.10, reflecting a stable operating margin around 35 % despite higher commodity costs. The firm remains exposed to macro-economic drivers such as disposable-income trends and regulatory risk; the FDA’s ongoing nicotine-reduction rulemaking could affect product mix and pricing elasticity across its core brands.
For a deeper quantitative assessment, you might explore ValueRay’s analyst toolkit.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 6.95b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.26 > 0.02 and ΔFCF/TA 1.43 > 1.0 |
| NWC/Revenue: -17.27% < 20% (prev -20.88%; Δ 3.61% < -1%) |
| CFO/TA 0.27 > 3% & CFO 9.29b > Net Income 6.95b |
| Net Debt (21.23b) to EBITDA (10.70b): 1.98 < 3 |
| Current Ratio: 0.61 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.68b) vs 12m ago -1.00% < -2% |
| Gross Margin: 69.56% > 18% (prev 0.70%; Δ 6886 % > 0.5%) |
| Asset Turnover: 59.57% > 50% (prev 58.12%; Δ 1.45% > 0%) |
| Interest Coverage Ratio: 9.70 > 6 (EBITDA TTM 10.70b / Interest Expense TTM 1.08b) |
Altman Z'' 5.61
| A: -0.10 (Total Current Assets 5.54b - Total Current Liabilities 9.15b) / Total Assets 35.02b |
| B: 1.03 (Retained Earnings 36.12b / Total Assets 35.02b) |
| C: 0.30 (EBIT TTM 10.47b / Avg Total Assets 35.10b) |
| D: 0.88 (Book Value of Equity 33.76b / Total Liabilities 38.47b) |
| Altman-Z'' Score: 5.61 = AAA |
Beneish M -3.13
| DSRI: 0.95 (Receivables 263.0m/270.0m, Revenue 20.91b/20.44b) |
| GMI: 1.01 (GM 69.56% / 70.27%) |
| AQI: 0.96 (AQ_t 0.79 / AQ_t-1 0.83) |
| SGI: 1.02 (Revenue 20.91b / 20.44b) |
| TATA: -0.07 (NI 6.95b - CFO 9.29b) / TA 35.02b) |
| Beneish M-Score: -3.13 (Cap -4..+1) = AA |
What is the price of MO shares?
As of February 04, 2026, the stock is trading at USD 62.23 with a total of 12,910,972 shares traded.
Over the past week, the price has changed by -1.19%, over one month by +8.58%, over three months by +11.82% and over the past year by +26.19%.
Over the past week, the price has changed by -1.19%, over one month by +8.58%, over three months by +11.82% and over the past year by +26.19%.
Is MO a buy, sell or hold?
Altria has received a consensus analysts rating of 3.27.
Therefor, it is recommend to hold MO.
- StrongBuy: 3
- Buy: 1
- Hold: 9
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the MO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 62.6 | 0.6% |
| Analysts Target Price | 62.6 | 0.6% |
| ValueRay Target Price | 76.7 | 23.3% |
MO Fundamental Data Overview January 31, 2026
P/E Trailing = 14.5049
P/E Forward = 10.6724
P/S = 4.3094
P/B = 27.3016
P/EG = 4.0147
Revenue TTM = 20.91b USD
EBIT TTM = 10.47b USD
EBITDA TTM = 10.70b USD
Long Term Debt = 24.13b USD (from longTermDebt, two quarters ago)
Short Term Debt = 1.57b USD (from shortTermDebt, last quarter)
Debt = 25.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 21.23b USD (from netDebt column, last quarter)
Enterprise Value = 121.55b USD (100.32b + Debt 25.71b - CCE 4.47b)
Interest Coverage Ratio = 9.70 (Ebit TTM 10.47b / Interest Expense TTM 1.08b)
EV/FCF = 13.40x (Enterprise Value 121.55b / FCF TTM 9.07b)
FCF Yield = 7.47% (FCF TTM 9.07b / Enterprise Value 121.55b)
FCF Margin = 43.40% (FCF TTM 9.07b / Revenue TTM 20.91b)
Net Margin = 33.23% (Net Income TTM 6.95b / Revenue TTM 20.91b)
Gross Margin = 69.56% ((Revenue TTM 20.91b - Cost of Revenue TTM 6.36b) / Revenue TTM)
Gross Margin QoQ = 62.11% (prev 72.60%)
Tobins Q-Ratio = 3.47 (Enterprise Value 121.55b / Total Assets 35.02b)
Interest Expense / Debt = 1.03% (Interest Expense 264.0m / Debt 25.71b)
Taxrate = 26.17% (396.0m / 1.51b)
NOPAT = 7.73b (EBIT 10.47b * (1 - 26.17%))
Current Ratio = 0.61 (Total Current Assets 5.54b / Total Current Liabilities 9.15b)
Debt / Equity = -7.34 (negative equity) (Debt 25.71b / totalStockholderEquity, last quarter -3.50b)
Debt / EBITDA = 1.98 (Net Debt 21.23b / EBITDA 10.70b)
Debt / FCF = 2.34 (Net Debt 21.23b / FCF TTM 9.07b)
Total Stockholder Equity = -3.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 19.79% (Net Income 6.95b / Total Assets 35.02b)
RoE = -215.2% (negative equity) (Net Income TTM 6.95b / Total Stockholder Equity -3.23b)
RoCE = 50.08% (EBIT 10.47b / Capital Employed (Equity -3.23b + L.T.Debt 24.13b))
RoIC = 34.57% (NOPAT 7.73b / Invested Capital 22.36b)
WACC = 4.85% (E(100.32b)/V(126.03b) * Re(5.90%) + D(25.71b)/V(126.03b) * Rd(1.03%) * (1-Tc(0.26)))
Discount Rate = 5.90% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.61%
[DCF Debug] Terminal Value 86.69% ; FCFF base≈8.89b ; Y1≈9.22b ; Y5≈10.49b
Fair Price DCF = 173.5 (EV 311.76b - Net Debt 21.23b = Equity 290.54b / Shares 1.67b; r=5.90% [WACC]; 5y FCF grow 3.86% → 2.90% )
EPS Correlation: 60.03 | EPS CAGR: 4.05% | SUE: -0.36 | # QB: 0
Revenue Correlation: 17.35 | Revenue CAGR: 5.29% | SUE: 0.02 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.25 | Chg30d=-0.008 | Revisions Net=-1 | Analysts=8
EPS current Year (2026-12-31): EPS=5.59 | Chg30d=-0.001 | Revisions Net=+0 | Growth EPS=+3.1% | Growth Revenue=+0.4%
EPS next Year (2027-12-31): EPS=5.80 | Chg30d=+0.018 | Revisions Net=+1 | Growth EPS=+3.9% | Growth Revenue=+0.5%
P/E Forward = 10.6724
P/S = 4.3094
P/B = 27.3016
P/EG = 4.0147
Revenue TTM = 20.91b USD
EBIT TTM = 10.47b USD
EBITDA TTM = 10.70b USD
Long Term Debt = 24.13b USD (from longTermDebt, two quarters ago)
Short Term Debt = 1.57b USD (from shortTermDebt, last quarter)
Debt = 25.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 21.23b USD (from netDebt column, last quarter)
Enterprise Value = 121.55b USD (100.32b + Debt 25.71b - CCE 4.47b)
Interest Coverage Ratio = 9.70 (Ebit TTM 10.47b / Interest Expense TTM 1.08b)
EV/FCF = 13.40x (Enterprise Value 121.55b / FCF TTM 9.07b)
FCF Yield = 7.47% (FCF TTM 9.07b / Enterprise Value 121.55b)
FCF Margin = 43.40% (FCF TTM 9.07b / Revenue TTM 20.91b)
Net Margin = 33.23% (Net Income TTM 6.95b / Revenue TTM 20.91b)
Gross Margin = 69.56% ((Revenue TTM 20.91b - Cost of Revenue TTM 6.36b) / Revenue TTM)
Gross Margin QoQ = 62.11% (prev 72.60%)
Tobins Q-Ratio = 3.47 (Enterprise Value 121.55b / Total Assets 35.02b)
Interest Expense / Debt = 1.03% (Interest Expense 264.0m / Debt 25.71b)
Taxrate = 26.17% (396.0m / 1.51b)
NOPAT = 7.73b (EBIT 10.47b * (1 - 26.17%))
Current Ratio = 0.61 (Total Current Assets 5.54b / Total Current Liabilities 9.15b)
Debt / Equity = -7.34 (negative equity) (Debt 25.71b / totalStockholderEquity, last quarter -3.50b)
Debt / EBITDA = 1.98 (Net Debt 21.23b / EBITDA 10.70b)
Debt / FCF = 2.34 (Net Debt 21.23b / FCF TTM 9.07b)
Total Stockholder Equity = -3.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 19.79% (Net Income 6.95b / Total Assets 35.02b)
RoE = -215.2% (negative equity) (Net Income TTM 6.95b / Total Stockholder Equity -3.23b)
RoCE = 50.08% (EBIT 10.47b / Capital Employed (Equity -3.23b + L.T.Debt 24.13b))
RoIC = 34.57% (NOPAT 7.73b / Invested Capital 22.36b)
WACC = 4.85% (E(100.32b)/V(126.03b) * Re(5.90%) + D(25.71b)/V(126.03b) * Rd(1.03%) * (1-Tc(0.26)))
Discount Rate = 5.90% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.61%
[DCF Debug] Terminal Value 86.69% ; FCFF base≈8.89b ; Y1≈9.22b ; Y5≈10.49b
Fair Price DCF = 173.5 (EV 311.76b - Net Debt 21.23b = Equity 290.54b / Shares 1.67b; r=5.90% [WACC]; 5y FCF grow 3.86% → 2.90% )
EPS Correlation: 60.03 | EPS CAGR: 4.05% | SUE: -0.36 | # QB: 0
Revenue Correlation: 17.35 | Revenue CAGR: 5.29% | SUE: 0.02 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.25 | Chg30d=-0.008 | Revisions Net=-1 | Analysts=8
EPS current Year (2026-12-31): EPS=5.59 | Chg30d=-0.001 | Revisions Net=+0 | Growth EPS=+3.1% | Growth Revenue=+0.4%
EPS next Year (2027-12-31): EPS=5.80 | Chg30d=+0.018 | Revisions Net=+1 | Growth EPS=+3.9% | Growth Revenue=+0.5%